CD274 and non-small cell lung carcinoma: In recent years, immune checkpoint inhibitors (ICIs) targeting the programmed death protein 1/programmed death ligand 1 (PD‐1/PD‐L1) pathway have shown a promising therapeutic effect against NSCLC, especially against tumors without driver mutations.